Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesElicio Therapeutics Inc.

Elicio Therapeutics Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.57 USD -0.06 ( 3.68%)
Last update at 2026-11-12T15:32:00Z
VOLUME
57189
Market Cap
52.30M

Momentum Score

…

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.55
Low
1.62
High
52 Week Price Range
1.92
Low
16.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Elicio Therapeutics Inc. is a clinical-stage biotechnology company focused on developing immune-modulating therapies for cancer and other diseases, though publicly available disclosures about its pipeline and platforms are limited. Long-term growth may be driven by clinical trial progress, regulatory milestones, strategic partnerships and successful commercialization of any approved therapies, so investors may find the company attractive for exposure to oncology immunotherapy development with upside tied to R&D outcomes.

The principal investment risks include binary clinical and regulatory outcomes, an ongoing need for external capital and potential dilution, competitive pressure from larger oncology developers, and the operational and execution risks typical of clinical-stage biotechs.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.63
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
8.87
ROE
-774.56%
Net Debt
-4.05M
ROCE
-212.45%
Diluted EPS TTM
-2.15

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -39.57M -51.90M -35.20M -28.21M -26.40M
Net income -39.57M -51.90M -35.20M -28.21M -26.40M
Selling general administrative 12.81M 11.33M 11.90M 5.63M 7.54M
Gross profit -1.13M -1.18M -1.17M - -
Reconciled depreciation 1.13M 1.18M 1.17M 0.39M 0.25M
Ebit -37.71M -51.44M -34.14M -23.67M -25.47M
Ebitda -36.59M -50.27M -32.97M -23.28M -25.22M
Depreciation and amortization 1.13M 1.18M 1.17M 0.39M 0.25M
Operating income -37.71M -44.99M -35.74M -23.73M -25.47M
Other operating expenses 37.71M 44.99M 35.74M 23.73M 25.47M
Interest expense 1.13M 0.46M 1.06M 3.60M 0.88M
Tax provision 0.00M 0.00M 0.00M - -
Interest income 0.78M 0.78M 0.37M 0.06M 0.00M
Net interest income -0.36M -3.18M -0.69M -3.53M -0.87M
Income tax expense - - - 3.60M 0.88M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 36.59M 43.81M 34.58M 23.73M 25.47M
Cost of revenue 1.13M 1.18M 1.17M - -
Total other income expense net -1.86M -6.91M 0.55M -0.94M -0.05M
Net income from continuing ops -39.57M -51.90M -35.20M -28.21M -26.40M
Net income applicable to common shares - - - -28.21M -26.40M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 25.86M 28.18M 27.15M 22.66M 14.81M
Other current assets 0.75M 3.08M 0.17M 0.04M 0.09M
Total liab 24.23M 39.49M 15.77M 124.81M 89.35M
Total stockholder equity 1.64M -11.31M 11.37M -102.15M -74.54M
Other current liab 6.43M 8.41M 0.04M 3.37M 2.96M
Common stock 0.18M 0.11M 0.10M 0.18M 0.17M
Capital stock 0.18M 0.11M 0.10M 0.18M 0.17M
Retained earnings -233.67M -194.10M -142.20M -107.01M -78.80M
Other liab - - - 0.09M 0.03M
Other assets - - - 3.45M -0.00M
Cash 18.56M 17.62M 12.89M 6.16M 9.28M
Total current liabilities 8.11M 11.52M 9.77M 6.87M 18.88M
Current deferred revenue - 1.17M 4.45M - 2.45M
Net debt -4.05M 8.42M -5.98M 1.33M 2.52M
Short term debt 1.01M 0.90M 0.91M 0.69M 11.80M
Short long term debt - - - - 11.80M
Short long term debt total 14.51M 26.04M 6.92M 7.48M 11.80M
Other stockholder equity 235.26M 182.85M 153.68M 4.69M 4.09M
Property plant equipment - - - 8.50M 0.89M
Total current assets 19.31M 20.69M 16.35M 10.72M 10.36M
Net tangible assets - - - -102.15M -74.54M
Long term debt 9.41M 20.03M - - -
Accounts payable 0.67M 1.04M 4.37M 2.81M 1.68M
Accumulated other comprehensive income -0.13M -0.17M -0.20M - -
Non currrent assets other 0.77M 0.60M 3.52M 3.45M 3.57M
Non current assets total 6.55M 7.49M 10.80M 11.95M 4.46M
Capital lease obligations 5.11M 6.01M 6.92M 7.48M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.08M -0.03M -0.65M -0.53M
Change to liabilities - - - 1.12M 0.03M
Total cashflows from investing activities -0.02M -0.08M -0.03M -0.65M -0.53M
Net borrowings 0.00M 19.73M 10.00M - 14.68M
Total cash from financing activities 36.70M 42.32M 38.61M 21.20M 19.39M
Change to operating activities - - - -0.61M 0.84M
Net income -39.57M -51.90M -35.20M -28.21M -26.40M
Change in cash -0.23M 5.19M 5.89M -1.63M -5.07M
Begin period cash flow 19.49M 14.30M 8.41M 10.04M 15.12M
End period cash flow 19.27M 19.49M 14.30M 8.41M 10.04M
Total cash from operating activities -36.95M -37.07M -32.69M -22.18M -23.94M
Issuance of capital stock 25.39M 5.63M 7.00M 21.12M 5.05M
Depreciation 1.13M 1.18M 1.17M 0.39M 0.25M
Other cashflows from investing activities - 0.00M 0.03M - -
Sale purchase of stock - -0.55M -0.15M - -
Other cashflows from financing activities 36.70M 16.96M 21.76M -0.65M 19.73M
Change to netincome - - - 5.12M 1.34M
Capital expenditures 0.02M 0.09M 0.07M 0.65M 0.53M
Change in working capital -3.44M 3.96M -0.06M 0.52M 0.87M
Stock based compensation 2.70M 1.45M 1.18M 0.58M 0.62M
Other non cash items 2.24M 8.24M 0.21M 3.60M 0.67M
Free cash flow -36.97M -37.16M -32.76M -22.83M -24.46M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
ELTX
Elicio Therapeutics Inc.		 -0.06
3.68%		 1.57 - - - 6.62 -2.61
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Elicio Therapeutics Inc.

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.

451 D Street, Boston, MA, United States, 02210

857 209 0050

https://elicio.com

33

Name Title Year Born
Mr. Robert T. Connelly CEO, President & Director 1960
Dr. Christopher M. Haqq M.D., Ph.D. Executive VP, Head of Research & Development and Chief Medical Officer 1966
Prof. Darrell J. Irvine Ph.D. Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board NA
Mr. Brian Piekos Chief Financial Officer 1975
Mr. Michael DiVecchia Senior Vice President of Operations & Human Resources NA
Dr. Peter DeMuth Ph.D. Chief Scientific Officer 1986
Ms. Megan C. Filoon General Counsel, Secretary & Compliance Officer NA
Ms. Esther Welkowsky Senior Vice President of Clinical Development NA
Ms. Joy Seymour VP & Head of Regulatory Affairs NA
Dr. Thian Kheoh Ph.D. Senior Vice President of Biometrics NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…